Medi-tate Ltd.

Olympus today announced positive study data for its minimally invasive iTind treatment for the symptoms of enlarged prostate.

The iTind procedure involves the placement of a temporary implanted nitinol device that reshapes the prostatic urethra. It does this without burning or cutting the prostate. Device placement can occur in an outpatient setting or physician office.

Olympus’ device remains in place for five to seven days while the patient stays at home. Upon removal, patients experience rapid and effective relief of their symptoms. Olympus acquired iTind when it acquired Medi-Tate, now a wholly-owned subsidiary, in May 2021.

It offers an alternative to pharmaceutical therapy, plus surgeries and permanent implants. It’s proven to relieve symptoms without affecting sexual and ejaculatory function or urinary continence.

Results from a long-term study showed long-lasting relief of more than four years for people with an enlarged prosta…

Olympus (TYO:7733) announced that it finalized the acquisition of benign prostatic hyperplasia (BPH) treatment developer Medi-Tate.

The Japanese conglomerate did not disclose the financial terms of the acquisition, which was finalized after the company exercised a call option in February, according to a news release.

Israel-based Medi-Tate develops the iTind device, which it designed as a flexible, three-strut nitinol device that can be placed during an in-office procedure. It expands over five days to create channels for allowing urine to flow and reshaping the prostate. Medi-Tate’s device won CE Mark approval in Europe in 2012.

Olympus previously held the exclusive right to distribute Medi-Tate products in the U.S. through a strategic investment dating back to 2018, having announced FDA de novo approval for the device in April 2020.

“The acquisition of Medi-Tate aligns with our corporate strategy of focusing on three priority therapeutic areas w…